Healthcare provider profile · identity verified

David M Dyck, MD

Allopathic & Osteopathic Physicians|Family Medicine · ELKHART, IN · NPI 1053303479

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show David M Dyck, MD received $185.51 in general payments during 2025 across 9 reported records.

Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 18.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 7 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$185.51

9 reported records · 8 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$34.19	18.4%	2	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$29.32	15.8%	1	2025
Abbott Laboratories	Unresolved — no canonical attribution shown	$23.12	12.5%	1	2025
Insulet Corporation	Unresolved — no canonical attribution shown	$23.04	12.4%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$20.42	11.0%	1	2025
Salix Pharmaceuticals, a division of Bausch Health US, LLC	Unresolved — no canonical attribution shown	$20.40	11.0%	1	2025
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$18.14	9.8%	1	2025
Esperion Therapeutics, Inc.	Unresolved — no canonical attribution shown	$16.88	9.1%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$166.66	8
Education	$18.85	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$34.19	2	2025
Source payment records 2025-01-10 · Boehringer Ingelheim Pharmaceuticals, Inc. · $15.34 · Open Payments source 2025-09-29 · Boehringer Ingelheim Pharmaceuticals, Inc. · $18.85 · Open Payments source
FREESTYLE LIBRE 3 Normalized: freestyle libre 3	Device	Abbott Laboratories	$23.12	1	2025
Source payment records 2025-11-10 · Abbott Laboratories · $23.12 · Open Payments source
Omnipod Normalized: omnipod	Device	Insulet Corporation	$23.04	1	2025
Source payment records 2025-04-16 · Insulet Corporation · $23.04 · Open Payments source
FARXIGA Normalized: farxiga	Drug	AstraZeneca Pharmaceuticals LP	$20.42	1	2025
Source payment records 2025-06-05 · AstraZeneca Pharmaceuticals LP · $20.42 · Open Payments source
XIFAXAN Normalized: xifaxan	Drug	Salix Pharmaceuticals, a division of Bausch Health US, LLC	$20.40	1	2025
Source payment records 2025-06-30 · Salix Pharmaceuticals, a division of Bausch Health US, LLC · $20.40 · Open Payments source
SHINGRIX Normalized: shingrix	Biological	GlaxoSmithKline, LLC.	$18.14	1	2025
Source payment records 2025-06-03 · GlaxoSmithKline, LLC. · $18.14 · Open Payments source
NEXLETOL Normalized: nexletol	Drug	Esperion Therapeutics, Inc.	$16.88	1	2025
Source payment records 2025-11-19 · Esperion Therapeutics, Inc. · $16.88 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
FARXIGA farxiga	2025	Farxiga	2024	18 Beneficiary count suppressed	exact normalized	Medicare Part D
JARDIANCE jardiance	2025	Jardiance	2024	137	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	18	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	28	suppressed by CMS
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	137	39
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	54	15
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	169	28

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	869	253
Levothyroxine Sodium	Levothyroxine Sodium	772	213
Lisinopril	Lisinopril	578	163
Amlodipine Besylate	Amlodipine Besylate	530	165
Metformin Hcl	Metformin Hcl	418	118
Hydrochlorothiazide	Hydrochlorothiazide	382	122
Omeprazole	Omeprazole	379	112
Metoprolol Succinate	Metoprolol Succinate	359	110
Losartan Potassium	Losartan Potassium	335	102
Pantoprazole Sodium	Pantoprazole Sodium	292	94
Simvastatin	Simvastatin	284	85
Albuterol Sulfate Hfa	Albuterol Sulfate	281	86
Rosuvastatin Calcium	Rosuvastatin Calcium	254	85
Gabapentin	Gabapentin	249	86
Meloxicam	Meloxicam	242	72
Alprazolam	Alprazolam	241	53
Tamsulosin Hcl	Tamsulosin Hcl	240	79
Glimepiride	Glimepiride	224	60
Zolpidem Tartrate	Zolpidem Tartrate	211	56
Trazodone Hcl	Trazodone Hcl	185	54
Escitalopram Oxalate	Escitalopram Oxalate	180	55
Sertraline Hcl	Sertraline Hcl	174	47
Furosemide	Furosemide	171	48
Ozempic	Semaglutide	169	28
Carvedilol	Carvedilol	149	51
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	143	42
Jardiance	Empagliflozin	137	39
Prednisone	Prednisone	135	97
Ezetimibe	Ezetimibe	134	48
Fluticasone Propionate	Fluticasone Propionate	131	66
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	130	36
Potassium Chloride	Potassium Chloride	124	37
Duloxetine Hcl	Duloxetine Hcl	122	33
Pravastatin Sodium	Pravastatin Sodium	120	32
Bupropion Xl	Bupropion Hcl	116	37
Montelukast Sodium	Montelukast Sodium	106	30
Mounjaro	Tirzepatide	105	27
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	98	42
Donepezil Hcl	Donepezil Hcl	97	27
Amoxicillin	Amoxicillin	92	82
Clopidogrel	Clopidogrel Bisulfate	92	29
Diclofenac Sodium	Diclofenac Sodium	90	32
Clonazepam	Clonazepam	89	28
Famotidine	Famotidine	86	30
Allopurinol	Allopurinol	84	23
Finasteride	Finasteride	84	25
Alendronate Sodium	Alendronate Sodium	82	20
Cephalexin	Cephalexin	82	70
Methylprednisolone	Methylprednisolone	82	74
Azithromycin	Azithromycin	81	77
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	76	17
Metoprolol Tartrate	Metoprolol Tartrate	76	22
Citalopram Hbr	Citalopram Hydrobromide	73	23
Warfarin Sodium	Warfarin Sodium	73	suppressed
Mirtazapine	Mirtazapine	72	16
Synthroid	Levothyroxine Sodium	71	18
Eliquis	Apixaban	70	19
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	70	20
Metformin Hcl Er	Metformin Hcl	69	24
Clonidine Hcl	Clonidine Hcl	68	18
Ciprofloxacin Hcl	Ciprofloxacin Hcl	66	58
Diazepam	Diazepam	66	14
Doxycycline Hyclate	Doxycycline Hyclate	66	63
Glipizide	Glipizide	63	24
Xarelto	Rivaroxaban	63	14
Tizanidine Hcl	Tizanidine Hcl	58	17
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	57	50
Hydralazine Hcl	Hydralazine Hcl	56	20
Hydroxyzine Hcl	Hydroxyzine Hcl	56	20
Lorazepam	Lorazepam	56	15
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	54	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	54	14
Atenolol	Atenolol	52	16
Celecoxib	Celecoxib	51	21
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	51	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	51	14
Tramadol Hcl	Tramadol Hcl	51	22
Triamcinolone Acetonide	Triamcinolone Acetonide	49	38
Pioglitazone Hcl	Pioglitazone Hcl	47	14
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	46	36
Chlorthalidone	Chlorthalidone	45	16
Amitriptyline Hcl	Amitriptyline Hcl	43	17
Pregabalin	Pregabalin	43	13
Quetiapine Fumarate	Quetiapine Fumarate	42	14
Meclizine Hcl	Meclizine Hcl	40	21
Sumatriptan Succinate	Sumatriptan Succinate	40	suppressed
Trulicity	Dulaglutide	39	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	38	13
Levofloxacin	Levofloxacin	37	31
Oxybutynin Chloride Er	Oxybutynin Chloride	37	15
Divalproex Sodium Er	Divalproex Sodium	35	suppressed
Humalog Kwikpen U-100	Insulin Lispro	35	11
Terazosin Hcl	Terazosin Hcl	35	suppressed
Januvia	Sitagliptin Phosphate	34	12
Oxybutynin Chloride	Oxybutynin Chloride	33	11
Fenofibrate	Fenofibrate	32	suppressed
Memantine Hcl	Memantine Hcl	32	11
Olmesartan Medoxomil	Olmesartan Medoxomil	32	suppressed
Ropinirole Hcl	Ropinirole Hcl	32	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	31	29
Mupirocin	Mupirocin	31	20
Tolterodine Tartrate Er	Tolterodine Tartrate	31	suppressed
Breo Ellipta	Fluticasone/Vilanterol	30	suppressed
Fluconazole	Fluconazole	30	20
Indomethacin	Indomethacin	30	suppressed
Spironolactone	Spironolactone	29	12
Topiramate	Topiramate	29	12
Wixela Inhub	Fluticasone Propion/Salmeterol	29	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	28	suppressed
Hydrocortisone	Hydrocortisone	28	15
Novolog Flexpen	Insulin Aspart	28	12
Ondansetron Hcl	Ondansetron Hcl	28	16
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Symbicort	Budesonide/Formoterol Fumarate	28	suppressed
Benazepril Hcl	Benazepril Hcl	27	suppressed
Ventolin Hfa	Albuterol Sulfate	27	13
Ibuprofen	Ibuprofen	26	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	26	suppressed
Sildenafil Citrate	Sildenafil Citrate	25	suppressed
Febuxostat	Febuxostat	24	suppressed
Glipizide Er	Glipizide	24	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	14
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	24	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	24	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	21	suppressed
Acyclovir	Acyclovir	20	11
Combivent Respimat	Ipratropium/Albuterol Sulfate	20	suppressed
Enalapril Maleate	Enalapril Maleate	20	suppressed
Nystatin	Nystatin	20	14
Propranolol Hcl	Propranolol Hcl	20	suppressed
Aripiprazole	Aripiprazole	19	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	19	suppressed
Epinephrine	Epinephrine	19	suppressed
Glyburide	Glyburide	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Lamotrigine	Lamotrigine	19	suppressed
Levetiracetam	Levetiracetam	19	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	18	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Nebivolol Hcl	Nebivolol Hcl	18	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	18	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Nabumetone	Nabumetone	17	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Bumetanide	Bumetanide	16	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Dexlansoprazole Dr	Dexlansoprazole	16	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	16	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Tradjenta	Linagliptin	16	suppressed
Diclofenac Potassium	Diclofenac Potassium	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	15	suppressed
Valsartan	Valsartan	15	suppressed
Clindamycin Hcl	Clindamycin Hcl	14	14
Desmopressin Acetate	Desmopressin Acetate	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Estradiol	Estradiol	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Lactulose	Lactulose	14	suppressed
Metronidazole	Metronidazole	14	13
Nifedipine Er	Nifedipine	14	suppressed
Spiriva Handihaler	Tiotropium Bromide	14	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	14	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Loperamide	Loperamide Hcl	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	suppressed
Raloxifene Hcl	Raloxifene Hcl	13	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Insulin Lispro	Insulin Lispro	11	suppressed
Klor-Con M20	Potassium Chloride	11	suppressed
Mesalamine Er	Mesalamine	11	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	11	suppressed
Ramipril	Ramipril	11	suppressed
Torsemide	Torsemide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$185.51 · 9 records	Boehringer Ingelheim Pharmaceuticals, Inc.	FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, NEXLETOL, Omnipod, SHINGRIX, XIFAXAN	5	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Farxiga play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error